TNFRSF8 and Hodgkins lymphoma: The most prominent approach of alternative therapy strategies in HL is the introduction of the CD30-directed antibody-drug conjugate brentuximab-vedotin or a second-line treatment option as a single agent into salvage protocols and with CT for the treatment of patients with previously untreated stage III or IV disease [230].